Abstract Intra-arterial radioembolization using microspheres labeled with the high-energy beta-emitter yttrium-90 ( 90 Y) is an innovative therapeutic strategy for primary and secondary hepatic malignancies. An accurate imaging workup plays a pivotal role in correctly selecting patients for treatment, to avoid severe complications and in assessment of the post-administration microsphere distribution. Nuclear medicine imaging modalities are an integral part of a complex multidisciplinary approach. In particular, hepatic perfusion imaging with 99m
Introduction
Primary liver cancer is the sixth most common cancer and the third cause of cancer-related death worldwide, responsible for 500,000 deaths per year [1] . Furthermore, the liver is the most common site of cancer metastases and up to 25 % of patients with malignancies will develop hepatic lesions, especially from colorectal, pancreatic and breast cancer. Fewer than 10 % of patients with hepatocellular carcinoma (HCC) or liver metastases are candidates for radical treatment, the majority being unsuitable due to advanced stage at presentation, presence of hepatic dysfunction or presence of co-morbidities. Local treatment, such as radiofrequency ablation or transarterial chemoembolization (TACE), and systemic therapy with cytotoxic drugs are alternative palliative treatments in patients with non-resectable disease.
Because of their characteristic blood supply, primarily from the hepatic artery, and their hypervascularization--they are up to three times more vascularized than normal parenchyma-liver lesions are suitable for loco-regional therapy by intra-arterial administration of drugs. Several techniques have been developed to selectively target liver tumors; these include administration of cytostatic drugs or intra-arterial embolization techniques. Intra-arterial radioembolization (RE) using microspheres labeled with the high-energy beta-emitter yttrium-90 ( 90 Y) is an innovative local therapy for conditions in which, to date, systemic therapy was the only option [2] . This procedure allows the tumor to be irradiated with a dose higher than that allowed by whole-liver external beam radiation treatment, in which doses are limited to 30-40 Gray (Gy). Radioembolization with 131 I-lipiodol has been used in patients with HCC as an adjuvant therapy, showing good results compared with chemoembolization even in patients with portal vein thrombosis, although without any survival advantage [3] . The retention of radiolabeled lipiodol in HCC after intraarterial infusion is related to embolization in the tumor microvessels and to its entry into the interstitium and into neoplastic cells and it shows an inverse relationship with tumor size. Several clinical studies have shown that treatment with 131 I-lipiodol is well tolerated and only rare cases of neutropenia and thrombocytopenia have been observed [4] [5] [6] [7] . Lipiodol has also been conjugated with renium-188 ( 188 Re) for the treatment of HCC and similar biodistribution data have been reported. Two phase II studies dealing with the treatment of advanced HCC showed that 188 Relipiodol treatment is feasible and well tolerated [8, 9] . Nowadays, selective internal radiation therapy (SIRT) performed with microspheres labeled with the high-energy beta-emitter 90 Y is increasingly being used for the treatment of patients with non-resectable primary or metastatic liver tumors. It can be performed by injection of the radiopharmaceutical into the proper hepatic artery or into the right (RHA) and left hepatic arteries (LHA) separately in the same session (whole-liver treatment), or into the RHA and LHA sequentially with a 4-week interval between the two injections (lobar treatment). Whole-liver treatment should be avoided in cases of HCC and carefully evaluated for the treatment of metastatic lesions; however, treatments should be as selective as possible to optimize efficacy and reduce side effects.
Yttrium-90 microspheres
In the 1960s, Blanchard et al. [10] explored the concept of intra-arterial RE by injecting 90 Y-containing microspheres into the hepatic artery of tumor-bearing rabbits. The favorable results of 90 Y-microsphere RE treatment in different animal models led to the clinical development of this technique in the 1970s. The first clinical investigations [11] [12] [13] [14] were conducted in the 1980s in selected patients and they gave encouraging results. However, the release of free isotope into the circulation due to leaking of 90 Y from the microspheres caused severe pancytopenia in several patients. In order to overcome the problem of degradation of the bond between 90 Y and the microspheres, new radiopharmaceuticals were developed. Two microsphere products are available commercially: one (Thera-Sphere Ò MDS Nordion, Canada) consists of glass microspheres containing native, non-radioactive yttrium-89 (which is then converted 90 Y by neutron irradiation), characterized by a mean diameter of 25 ± 1 lm and high specific activity (2,500 Bq per sphere). In this case, the in vitro release of 90 Y is less than 0.13 % after 6 weeks of incubation in saline solution. The other commercially available product consists of 90 Y resin microspheres (SIR-Spheres Ò SirTex Ltd, Australia), characterized by a mean diameter of 32 ± 10 lm and a lower specific activity (50 Bq per sphere). Labeling of these microspheres with 90 Y is based on cation exchange, a reversible process in isotonic solution. In this case, stability studies showed that the release of 90 Y is \0.4 % in water after 20 min of incubation and the levels in blood and urine of treated patients are inferior to 50 KBq/L. The standard activity per vial is 3 GBq, corresponding to 1.2 and 40-80 million microspheres for the glass-based and resin-based products, respectively. The embolic effect of resin microspheres could result in a therapeutic advantage due to the related ischemia, but also in side effects such as pain, fever and nausea, especially in patients with cirrhosis.
Imaging work-up prior to SIRT
The incidence of gastrointestinal complications following RE has been found to range from 3 to 5 % [15] , sometimes exceeding 10 %. The major causes of gastroduodenal ulcers are the extrahepatic infusion of radiolabeled microparticles through arteries originating from the hepatic arterial branches and microsphere reflux occurring during the injection. An accurate imaging workup prior to 90 Ymicrosphere administration is a crucial part of the therapeutic management of patients undergoing RE to correctly select those who may benefit from the therapy. An angiographic evaluation of the visceral arteries prior to RE should also be performed to evaluate anatomical variants and extrahepatic arteries feeding the tumor. Moreover, 99m Tc-MAA scintigraphy plays a pivotal role in identifying gastroduodenal accumulation and lung shunt.
Angiographic evaluation
To establish the vessel anatomy, abdominal aortography followed by selective visceral angiography is performed. Furthermore, superior mesenteric arteriography should also be performed to evaluate the presence of accessory or replaced hepatic arteries. The status of the portal vein may be assessed with angiograms acquired during the venous phase, even though this information can be obtained with CT/MRI. Selective right and left hepatic angiography allows identification of any variant mesenteric anatomy and subsequent prophylactic embolization of extrahepatic vessels such as the right gastric, gastroduodenal or falciform artery. Normal celiac trunk anatomy is present in only 55 % of patients. In these cases the proper hepatic artery originates from the common hepatic artery, which also gives rise to the gastroduodenal artery. The proper hepatic artery continues as the right hepatic artery, giving off the left hepatic artery. The most common anatomical variants, occurring in 10 % of cases, consist of a left hepatic artery originating from the left gastric artery or a right replaced hepatic artery originating from the superior mesenteric artery. In about 8 % of cases, an accessory right (7 %) and left (8 %) hepatic artery may originate, respectively, from the left gastric and the superior mesenteric artery [16] . The extrahepatic vessels originating from the hepatic arteries have to be occluded in order to isolate the hepatic circulation ( Fig. 1) [17, 18] . The largest extrahepatic vessel, originating from a hepatic artery, is the gastroduodenal artery. The next most important extrahepatic vessel is the right gastric artery, most often originating from the proper or left hepatic artery. The falciform artery is a less common extrahepatic artery, but failure to identify and embolize it may cause severe complications such as abdominal pain, peri-umbilical skin rash and skin necrosis. Other vessels that may be identified and may require prophylactic embolization include the supraduodenal, retroduodenal, left inferior phrenic, accessory left gastric and inferior esophageal arteries. A detailed evaluation during angiography should be performed to make certain that hepatic arteries do not originate from an extrahepatic vessel. In fact the anatomy of the gastroduodenal artery should be carefully explored and embolization avoided if it is found to supply the hepatic parenchyma. Prophylactic embolization of the cystic artery is a controversial practice because it may lead to ischemic cholecystitis [19] . Furthermore, the gallbladder may also be supplied by collaterals or perforators from the hepatic parenchyma and the incidence of radiation-induced cholecystitis is very low. It may be difficult to establish whether a vessel is a hepatic or extrahepatic branch or a combination. In such cases, computed tomography (CT) angiography with intravenous or intraarterial contrast-injection may help to identify the correct anatomy [20] .
Hepatic perfusion imaging
Liver perfusion imaging with 99m Tc-MAA, serving to identify sites of non-targeted distribution of the radiopharmaceutical or the presence of lung shunt, is an indispensable step before RE with 90 Y-microspheres. The radiotracer is injected during angiography (185 MBq) into the branch of the hepatic artery supplying the target volume to simulate the treatment with 90 Y-microspheres. If the whole liver is being evaluated for treatment, the usual dose injected into the right and left hemi-liver is approximately 111 MBq (3 mCi) and 74 MBq (2 mCi), respectively. The 99m Tc-MAA used in pretreatment investigative perfusion studies are 30-90 nm in diameter, similar in range but not identical in size and shape to 90 Y-microspheres. Anterior and posterior planar images of the whole body are obtained within 1 h of MAA injection to calculate the fraction of 99m Tc-MAA shunted to the lungs (Fig. 2) and to detect any extrahepatic accumulation of radiopharmaceutical. The limit of injected activity shunted to the lungs with TheraSpheres is 610 MBq/mL [21] . As regards SIR-Spheres, the proposed activity for the treatment should be adjusted to the percentage of hepatopolmunary lung shunting, and in the presence of a value superior to 20 %, administration of SIR-Spheres is contraindicated [22] . These limitations are applied to avoid exceeding a maximum radiation dose of 30 Gy to the lungs [23] . circulation should be correctly evaluated. In this latter circumstance scintigraphy will reveal the presence of activity in the thyroid gland, kidneys and stomach (Fig. 3) . A delay in image acquisition after the angiographic procedure may result in significant in vivo degradation of the radiopharmaceutical with high background activity and should, therefore, be avoided. Any activity visualized in the stomach should be carefully evaluated to distinguish between free 99m Tc-pertechnetate (which characteristically involves the entire gastric mucosa as well as the thyroid gland) and extrahepatic perfusion, which is imaged as a focal area of accumulation in the stomach wall. The administration of perchlorate before angiography prevents non-specific uptake of 99m Tc-pertechnetate in the thyroid and stomach. The extrahepatic sites of 99m Tc-MAA accumulation are unlikely to be detectable on planar images because of the low spatial resolution; thus SPECT of the abdomen should be performed to avoid severe complications after SIRT (Fig. 4) . Careful analysis of tomographic images is important to accurately distinguish whether the 99m Tc-MAA has accumulated in the liver or in adjacent organs (Fig. 5) . SPECT/CT more accurately identifies sites of extrahepatic activity than does SPECT or planar imaging only. Ahmadzadehfar and colleagues [26] reported that extrahepatic accumulation was detected by planar imaging, SPECT and SPECT/CT in 12, 17 and 42 % of examinations, respectively. The SPECT/CT findings affected management in 29 % of patients. The sensitivities were 100, 41 and 32 % and the specificities 98, 98 and 93 % for SPECT/CT, SPECT and planar imaging, respectively. In a prospective study Hamami et al. [27] , evaluating 68 99m Tc-MAA procedures performed in 58 patients with HCC, demonstrated a superior performance of SPECT/CT over SPECT and planar imaging (sensitivity 100 %, specificity 94 % for SPECT/CT versus 56 and 87 %, respectively, for SPECT). Similarly, in a report published by Lenoir et al.
[28] the superiority of SPECT/CT over planar imaging was demonstrated analyzing 136 hepatic perfusion scintigraphies. In *36 % of the cases SPECT/CT had a potential impact on patient management. In a study by Dudeck et al.
[29] on repeated angiography in patients designated for 90 Y RE in the event of extrahepatic 99m TcMAA accumulation, gastroduodenal uptake was identified in 33 patients (9.7 %) using SPECT/CT. During the subsequent angiography procedure the gastroduodenal shunt was correctly identified and corrected in 31 out of the 33 patients. A discrepancy between the distribution of 99m Tc-MAA in the liver and the vascular territory to be treated may occur in a small percentage (\4 %) of cases and can be explained by different injection rates and different arterial flow between soluble Fig. 2 Hepatic perfusion study planar image (a anterior view; b posterior view) demonstrating severe lung shunt (a contraindication to the treatment) (color figure online) Fig. 3 Whole-body study (anterior view) in a patient submitted to 99m Tc-MAA scintigraphy revealing the presence of activity in the thyroid gland, kidneys and stomach due to free 99m Tc-pertechnetate (color figure online) contrast molecules versus 99m Tc-MAA, or to different locations of the microcatheter tip between the diagnostic phase and the treatment phase. Kao and colleagues [30] showed that 99m Tc-MAA SPECT/CT more accurately represents hepatic microparticle biodistribution than does soluble contrast hepatic angiography. Alternatively, the tumor may have an unidentified accessory arterial blood supply or may have caused vascular remodeling of the local arteries. This possibility is more common in patients previously submitted to TACE treatment of the primary tumor-supplying arteries. SPECT/CT plays a pivotal role in treatment planning, making it possible to determine liver volume and dosimetry prior to injecting radiolabeled 90 Ymicrospheres.
Treatment planning with 99m Tc-MAA SPECT
The methods most commonly used to determine the activity of 90 Y-microspheres to be administered (delivered absorbed dose of 120 ± 20 Gy in the injected region for glass particles and BSA method for resin particles) should be replaced by the evaluation of tumor and non-tumor individual absorbed dose. The relationship between the 99m Tc-MAA SPECT-based tumor absorbed dose and tumor response is reported in several studies investigating the possibilities of treatment optimization by individualized 99m Tc-MAA SPECT-based dose planning. All published studies found a dose-efficacy correlation: with resin spheres, both in HCC [31] and in CRC metastases [32, 33] , and with glass spheres in HCC [34, 35] . Statistically significant differences in the most important oncological end points, i.e., overall survival, progression-free survival and time to progression, were correlated with lesion absorbed doses higher or lower than about 200 Gy with glass spheres in HCC [36, 37] . As regards radio-induced liver toxicity, Sangro et al. [38] found that the threshold for RE-induced liver disease (REILD) with resin spheres is an activity greater than 0.8 GBq/L, which corresponds to 50 Gy kg/ GBq 9 0.8 GBq/1 kg = 40 Gy mean absorbed dose to non-tumoral parenchyma. On multivariate analysis repeated on the subset of REILD patients, young age and mean absorbed dose to non-tumoral parenchyma emerged as independent risk factors. Chiesa et al. [39] found the first dose-toxicity correlation for glass spheres, the limit of 70 Gy averaged on the whole non-tumoral parenchyma being found to keep liver failure risk below 20 %. The difference in the healthy liver dose limit for the two kinds of spheres seems attributable to the different number of particles and consequent differences in non-uniformity of dose distribution at the microscopic level. Methodologically, because of permanent trapping of microspheres (absence of biological clearance), SPECT imaging can be acquired at any time after administration. Simple patient-specific quantification is based on the counts-to-activity calibration factor obtained as the total injectable 90 Y-microsphere activity divided by total counts in the 99m Tc-MAA SPECT field of view. Absorbed dose D is computed using the well-known approximation of the MIRD formalism:
, where A is the activity in a region, determined through counts in a ROI defined over that region and the calibration factor, and M is its mass, measured on SPECT and/or CT. The only requirement for this methodology is an attenuation-corrected 99m Tc-MAA SPECT study, which is intrinsically provided by a hybrid SPECT/CT single gantry [40] .
A limitation of pre-treatment dosimetry is the possible mismatch between 99m Tc-MAA and 90 Y-microsphere biodistributions. This may arise not only from an intentionally or inadvertently different catheter position, but also from intrinsic differences in the number of particles. The number of albumin particles is significantly lower than the number of injected 90 Y-microspheres (0.1-0.2 millions of MAA versus 30-60 millions of resin and 4-5 millions of glass particles), and a similar pattern is seen with the density (1.1 versus 1.6 g/mL for resin and 3.3 g/mL for glass particles). These features might explain why the mismatch problem seems to be more serious for embolic resin spheres [41] [42] [43] . The literature is controversial, however, since Kao et al. [44] , for instance, found excellent correspondence between 99m Tc-MAA SPECT and 90 Y PET dosimetry (median relative error 3.8 %).
Post-treatment imaging workup
Quantitative assessment of post-administration intrahepatic microsphere distribution is important for evaluation of RE toxicity and efficacy and can potentially be used for the prediction of patient response and patient-specific therapeutic dose optimization. Considering the mainly beta emission of the radionuclide, the in vivo imaging of 90 Y to determine tumor targeting and to perform dosimetric studies is challenging. Furthermore, the biodistribution of 99m Tc-MAA may imperfectly predict that of 90 Y-labeled microspheres. The possibilities for imaging distribution of 90 Y-microspheres include SPECT acquisition using the bremsstrahlung emission and PET/CT using the transition of 90 Y to zirconium-90. Although bremsstrahlung imaging of 90 Y is widely used in clinical practice, in the absence of a photopeak, SPECT imaging is dependent on the continuous bremsstrahlung X-rays; this results in low spatial resolution and poor quantification performance. The absence of a photopeak prohibits the use of simple window-based scatter rejection, scatter correction, and attenuation correction techniques, and penetration of highenergy photons through the collimator septa leads to further loss of image contras. Several reconstruction algorithms and imaging protocols have been proposed to overcome these technical limitations [41, 45] . The use of pinhole collimators seems to result in better contrast recovery coefficients compared with those obtained with parallel-hole collimators. The different designs and the attenuating material used for the collimation may explain these data [46] . Ahmadzadehfar et al. [47] evaluated the significance of post-therapy bremsstrahlung SPECT/CT images in the prediction of RE-induced extrahepatic side effects in 188 procedures. The results showed that detection of extrahepatic activity on bremsstrahlung SPECT/CT scans predicted gastrointestinal ulcers with a sensitivity of 87 % and a specificity of 100 %, despite low image quality. The positron emission of 90 Y (32 positrons per second per MBq) with a maximum energy of 758 keV is suitable for PET imaging, allowing the detection of extrahepatic activity and accurate tumor and liver dose estimation. Moreover, the correction techniques for scatter, random, and attenuation effects that are clinically available for 18 F PET can be directly applied to 90 Y PET. Carlier and colleagues [48] demonstrated that the minimum radioactive concentration of 90 Y detectable by PET imaging is 1 MBq/ mL. An activity concentration below 1 MBq/mL may also be detected, but with a variable quantitative accuracy depending on the lesion size and reconstruction parameters. The benefit of time-of-flight reconstruction has been shown particularly for concentrations below 2 MBq/mL or small lesion sizes. Evaluation of 90 Y-particle accumulation with PET/CT demonstrates high spatial resolution and low scatter compared with bremsstrahlung SPECT/CT (Fig. 6 ). Elschot and colleagues [49] showed that the image quality of PET is superior to bremsstrahlung SPECT for the assessment of 90 Y-microsphere distribution after RE. PET showed higher contrast recovery coefficients than SPECT. PET-based dose estimates were more accurate than SPECT-based dose estimates, with underestimations ranging from 45 to 11 % for PET, and 75 to 58 % for SPECT, respectively. Padia et al. [50] demonstrated that PET/CT shows spatial resolution at least comparable to that of 99m Tc-MAA SPECT/CT in patients with large ([5 cm) HCC. Quantitative uptake in non-treated regions of interest showed significantly reduced scatter with PET/CT versus SPECT/CT (1 versus 14 %). The in vivo biodistribution of holmium microspheres may be studied with nuclear medicine imaging or MRI. In a study performed by Turner et al. [51] a tracer activity of 166 Ho-microspheres was administered in pigs to predict the total administered activity required to deliver a prescribed radiation absorbed dose to the liver (25 Gy).
166 Ho-PLLA-MS SPECT imaging was found to be useful for quantitative analysis and for correctly calculating the absorbed dose. The pretreatment scout dose may be helpful for adjusting the delivered activity and the treatment dose distribution can be evaluated in a similar way. Finally, 166 Ho-microspheres could also be administered under real-time MRI guidance, with direct visualization of the microsphere distribution. Postadministration intrahepatic microsphere distribution was first evaluated with MRI in phantom and animal models by Nijsen and colleagues [52] , who showed that Ho-PLLA-MS can be imaged clearly in vivo with MRI. Estimation of the absorbed radiation dose with MRI was performed in 15 patients submitted to whole-liver treatment . SPECT images were also acquired 3-6 days after administration of Ho-PLLA-MS. The mean whole-liver absorbed radiation dose calculated on MRI correlated with the absorbed radiation dose on SPECT and a more detailed intra-tumor biodistribution assessment was possible due to the better spatial resolution of MRI. F]FDG PET imaging was found to be more sensitive than CT in the assessment of early response in a study performed by Szyszko et al. [55] . Eighty-six percent of patients showed decreased PET activity at 6 weeks while only 13 % showed a partial response in the size of tumor on CT scan. Assessment of early responses with [ 18 F]FDG PET/CT has been found to be superior to assessment based on the RECIST criteria and changes in tumor density evaluated with CT. Furthermore, PET is the strongest predictor of progression-free survival in patients with liver metastases, demonstrating a correlation with tumor markers [56] [57] [58] .
Future perspectives
Holmium poly(L-lactic acid) (PLLA) microspheres (Ho-PLLA-MS) containing neutron-activable 165 Ho were proposed as suitable candidates for RE treatment of hepatic malignancies in the early 1990s by Mumper and colleagues [59] . Holmium-l66 ( 166 Ho) is a beta (E max 1.84 MeV, halflife of 27 h) and gamma emitter (81 keV) with a maximum soft-tissue range of 8.4 mm suitable for imaging with a gamma camera. The absorbed radiation dose per Bq of 166 Ho is lower than that of 90 Y (8.7 versus 28 mGy/MBq) due to their different physical characteristics. Nijsen et al. [60, 61] developed 166 Ho-PLLA-MS with a higher content of holmium (17 versus 9 %) and showed elevated retention in liver tumor ([95 %) in an animal model. The PLA microspheres, which have a mean diameter of 30 lm (range 20-50 lm), are biodegradable and result in no permanent liver embolization. Holmium is highly paramagnetic and can consequently be visualized by MRI. A recent phase I dose escalation study evaluated the safety and the maximum tolerated radiation dose (MTRD) of 166 Ho RE in 15 patients with liver metastases. The MTRD was identified as 60 Gy. Stable disease or partial response was achieved in 14 out of 15 patients at 6 weeks and in nine out of 14 patients (64, 95 % CI 39-84) at 12 weeks after SIRT [62] .
Conclusion
Intra-arterial RE using microspheres labeled with the highenergy beta-emitter 90 Y is a promising therapy for primary and secondary liver tumors. The process of selecting patients to be treated involves several imaging techniques and is designed to optimize the clinical benefits and to avoid severe hepatic and extrahepatic complications. A pivotal role in the workup of these patients is played by nuclear imaging modalities, from 99m TC-MAA for the evaluation of hepatic perfusion to [ 18 F]FDG PET for the assessment of response. Nuclear medicine also plays a crucial role in the evaluation of tumor and non-tumor individual absorbed dose, allowing treatment optimization through individualized dose planning and the relative correlation with patient outcome.
